BioCentury
ARTICLE | Management Tracks

Mott retires from NEA

March 5, 2020 1:52 AM UTC

Dave Mott, the former Smith Barney investment banker, CEO of MedImmune and longtime VC, has announced his retirement from New Enterprise Associates. Mott, who has led the firm’s biopharma practice since 2008, plans to focus on family and investing via Mott Family Capital while continuing to serve as chairman of multiple biotech boards, according to a letter Mott sent to BioCentury.

Prior to NEA, Mott had a 16-year tenure at MedImmune Inc., where he served in various positions including CFO and COO before taking the helm as president and CEO in 2000. He led the 2007 sale of MedImmune to AstraZeneca plc (LSE:AZN; NYSE:AZN) for $15.6 billion, and served as an EVP at AZ after the acquisition. ...

BCIQ Company Profiles

New Enterprise Associates